Table 3. Summary of pivotal study MRI data by dose group.

MRI Index	Treatment	Baseline (t = 8 wk)	Endpoint (t = 16 wk)	Paired t-test p value
Scar mass (g)	Placebo	6.1±1.9	7.2±2.4	<0.001
	CSps	6.7±3.1	6.4±2.6	ns
Scar size (% of LV)	Placebo	10.9±2.3	11.5±2.4	0.026
	CSps	11.1±3.2	9.5±2.7	<0.001
Viable myocardium (g)	Placebo	50.0±6.3	54.7±6.5	<0.001
	CSps	51.9±6.8	60.0±6.9	<0.001
LV mass (g)	Placebo	56.1±7.6	61.9±8.1	<0.001
	CSps	58.6±9.2	66.4±8.9	<0.001
LVEF (%)	Placebo	42.1±7.0	40.9±7.7	ns
	CSps	43.6±5.2	43.2±5.1	ns
EDV (ml)	Placebo	80.8±21.7	93.2±20.1	0.001
	CSps	81.7±15.5	89.0±23.5	ns
ESV (ml)	Placebo	48.0±18.3	56.3±19.3	0.002
	CSps	46.7±13.6	51.5±19.7	Ns
Body weight gain (kg)	Placebo	n/a	+12.5±3.8	ns (Ind t-test)
	CSps	n/a	+14.0±4.7
HR during MRI (bpm)	Placebo	n/a	112±13	ns (Ind-t-test)
	CSps	n/a	99±18